Omeros' (OMER) Overweight Rating Reaffirmed at Cantor Fitzgerald

Omeros (NASDAQ:OMER - Get Free Report)'s stock had its "overweight" rating restated by stock analysts at Cantor Fitzgerald in a report released on Wednesday, Marketbeat reports. They currently have a $22.00 target price on the biopharmaceutical company's stock. Cantor Fitzgerald's target price indicates a potential upside of 16.53% from the stock's current price.

A number of other research firms have also issued reports on OMER. Zacks Research lowered shares of Omeros from a "strong-buy" rating to a "hold" rating in a research note on Monday, July 13th. Weiss Ratings raised shares of Omeros from a "hold (c-)" rating to a "hold (c)" rating in a research report on Thursday, October 8th. HC Wainwright restated a "buy" rating on shares of Omeros in a report on Monday, July 27th. Finally, Wall Street Zen raised Omeros from a "hold" rating to a "buy" rating in a research report on Saturday, August 15th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $34.00.

Omeros Trading Down 3.8%

Shares of NASDAQ:OMER opened at $18.88 on Wednesday. The stock has a market capitalization of $1.37 billion, a PE ratio of 14.75 and a beta of 2.57. Omeros has a 1 year low of $4.05 and a 1 year high of $21.24. The firm has a fifty day moving average price of $18.12 and a 200 day moving average price of $13.72.

Omeros (NASDAQ:OMER - Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The biopharmaceutical company reported $0.02 EPS for the quarter, beating analysts' consensus estimates of ($0.27) by $0.29. The firm had revenue of $28.53 million during the quarter, compared to the consensus estimate of $12.69 million. On average, sell-side analysts forecast that Omeros will post -0.37 earnings per share for the current fiscal year.

Insider Activity at Omeros

In other Omeros news, Director Arnold C. Hanish sold 10,000 shares of the firm's stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $18.95, for a total value of $189,500.00. Following the sale, the director directly owned 5,000 shares in the company, valued at $94,750. This trade represents a 66.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Peter B. Cancelmo sold 25,000 shares of the firm's stock in a transaction on Monday, August 31st. The stock was sold at an average price of $18.54, for a total transaction of $463,500.00. Following the completion of the sale, the vice president owned 200 shares in the company, valued at $3,708. This represents a 99.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 105,906 shares of company stock worth $1,989,705. 10.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. BlackRock Inc. acquired a new stake in Omeros during the second quarter worth about $57,484,000. State Street Corp raised its holdings in Omeros by 20.9% in the 2nd quarter. State Street Corp now owns 2,319,906 shares of the biopharmaceutical company's stock valued at $22,062,000 after acquiring an additional 400,331 shares in the last quarter. Corient Private Wealth LLC raised its holdings in Omeros by 13.0% in the 4th quarter. Corient Private Wealth LLC now owns 688,025 shares of the biopharmaceutical company's stock valued at $11,817,000 after acquiring an additional 79,263 shares in the last quarter. Corient Private Wealth LP bought a new stake in shares of Omeros in the 2nd quarter worth approximately $6,274,000. Finally, Bank of America Corp DE lifted its position in shares of Omeros by 57.8% in the 1st quarter. Bank of America Corp DE now owns 204,805 shares of the biopharmaceutical company's stock worth $2,163,000 after acquiring an additional 74,997 shares during the period. Institutional investors and hedge funds own 48.79% of the company's stock.

Omeros Company Profile

Omeros Corporation NASDAQ: OMER is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994.

Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway.